Atrial fibrillation ablation as first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF): evaluating the impact on patient survival

References

• Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337(19):1360–1369.
   PubMed Web of Science ®Google Scholar
• Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med. 1999;341(12):910–911.
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation. 1998;98(23):2574–2579.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. Circulation. 2003;107(23):2920–2925.
   PubMed Web of Science ®Google Scholar
• Chiang C-E, Naditch-Brûlé L, Murin J, et al. Distribution and Risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice. Circ Arrhythm Electrophysiol. 2012;5(4):632–639.
   PubMed Web of Science ®Google Scholar
• Carlisle MA, Fudim M, DeVore AD, et al. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019;7(6):447–456.
   PubMed Web of Science ®Google Scholar
• Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356.
   PubMed Web of Science ®Google Scholar
• Lardizabal JA, Deedwania PC. Atrial fibrillation in heart failure. Med Clin North Am. 2012;96(5):987–1000.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics—2015 Update. Circulation. 2015;131(4):e29–e322.
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–162.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics—2019 Update: a Report From the American Heart Association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of Atrial Fibrillation in the 21st Century. Circ Res. 2020;127(1):4–20.
   PubMed Web of Science ®Google Scholar
• Deshmukh A, Iglesias M, Khanna R, et al. Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2. 2022;3(5):577–586
   PubMedGoogle Scholar
• Cleland J. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442–463.
   PubMed Web of Science ®Google Scholar
• Nattel S. Ionic Determinants of Atrial Fibrillation and Ca2+ Channel Abnormalities. Circ Res. 1999;85(5):473–476.
   PubMed Web of Science ®Google Scholar
• den Berg Mp V, Tuinenburg AE, Crijns HJ, et al. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997;77(4):309–313.
   PubMed Web of Science ®Google Scholar
• Schorb W, Conrad K, Singer H, et al. Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. J Mol Cell Cardiol. 1995;27(5):1151–1160.
   PubMed Web of Science ®Google Scholar
• Tsai C-T, Lai L-P, Kuo K-T, et al. Angiotensin II Activates Signal Transducer and Activators of Transcription 3 via Rac1 in Atrial Myocytes and Fibroblasts. Circulation. 2008;117(3):344–355
   PubMed Web of Science ®Google Scholar
• Abed HS, Wittert GA, Leong DP, et al. Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation. Jama. 2013;310(19):2050.
   PubMed Web of Science ®Google Scholar
• C-h L, Akazawa H, Tamagawa M, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A–mediated fibrosis in pressure-overloaded mouse hearts. J Clin Investig. 2010;120(1):242–253.
   PubMed Web of Science ®Google Scholar
• Y-C Q, Y-M D, S-L W, et al. Activated nuclear factor-κB and increased tumor necrosis factor-α in atrial tissue of atrial fibrillation. Scan Cardiovasc J. 2009;43(5):292–297.
   PubMed Web of Science ®Google Scholar
• Tomaselli G. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42(2):270–283.
   PubMed Web of Science ®Google Scholar
• Narayan SM, Franz MR, Clopton P, et al. Repolarization Alternans Reveals Vulnerability to Human Atrial Fibrillation. Circulation. 2011;123(25):2922–2930.
   PubMed Web of Science ®Google Scholar
• Naito M, David D, Michelson EL, et al. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J. 1983;106(2):284–291.
   PubMed Web of Science ®Google Scholar
• Rahimtoola SH, Ehsani A, Sinno MZ, et al. Left atrial transport function in myocardial infarction. Am J Med. 1975;59(5):686–694.
   PubMed Web of Science ®Google Scholar
• Clark DM, Plumb VJ, Epstein AE, et al. Hemodynamic Effects of an Irregular Sequence of Ventricular Cycle Lengths During Atrial Fibrillation. J Am Coll Cardiol. 1997;30(4):1039–1045.
   PubMed Web of Science ®Google Scholar
• Deshmukh P, Krishnamani R, Romanyshyn M, et al. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med. 2004. 10.3892/ijmm.13.3.455.
   PubMed Web of Science ®Google Scholar
• Kotecha D, Lam CSP, Van Veldhuisen DJ, et al. Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. J Am Coll Cardiol. 2016;68(20):2217–2228.
   PubMed Web of Science ®Google Scholar
• Møller M, Torp-Pedersen CT, Køber L. Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction: safety Aspects and Effect on Atrial Fibrillation. Congestive Heart Failure 2001;7(3):146–155
   PubMedGoogle Scholar
• Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction. N Engl J Med. 1999;341(12):857–865.
   PubMed Web of Science ®Google Scholar
• Freudenberger RS, Wilson AC, Kostis JB. Comparison of Rate Versus Rhythm Control for Atrial Fibrillation in Patients With Left Ventricular Dysfunction (from the AFFIRM Study). Am J Cardiol. 2007;100(2):247–252.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med. 2002;347(23):1825–1833.
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. N Engl J Med. 2008;358(25):2667–2677.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Krupadev V, Dagher L, et al. Pharmacological rhythm versus rate control in patients with atrial fibrillation and heart failure: the CASTLE-AF trial. J Interv Card Electrophysiol. 2020;61(3):609–615.
   PubMed Web of Science ®Google Scholar
• Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004;43(6):1004–1009.
   PubMed Web of Science ®Google Scholar
• Khan MN, Jaïs P, Cummings J, et al. Pulmonary-Vein Isolation for Atrial Fibrillation in Patients with Heart Failure. N Engl J Med. 2008;359(17):1778–1785.
   PubMed Web of Science ®Google Scholar
• Passantino A, Lagioia R, Mastropasqua F, et al. Short-Term Change in Distance Walked in 6 Min Is an Indicator of Outcome in Patients With Chronic Heart Failure in Clinical Practice. J Am Coll Cardiol. 2006;48(1):99–105.
   PubMed Web of Science ®Google Scholar
• MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2010;97(9):740–747.
   PubMed Web of Science ®Google Scholar
• Jones DG, Haldar SK, Hussain W, et al. A Randomized Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Heart Failure. J Am Coll Cardiol. 2013;61(18):1894–1903.
   PubMed Web of Science ®Google Scholar
• Flynn KE, Lin L, Moe GW, et al. Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. Am Heart J. 2012;163(1):88–94.e3.
   PubMed Web of Science ®Google Scholar
• Swank AM, Horton J, Fleg JL, et al. Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure Patients. Circulation. 2012;5(5):579–585.
   PubMed Web of Science ®Google Scholar
• Hunter RJ, Berriman TJ, Diab I, et al. A Randomized Controlled Trial of Catheter Ablation Versus Medical Treatment of Atrial Fibrillation in Heart Failure (The CAMTAF Trial). Circ Arrhythm Electrophysiol. 2014;7(1):31–38.
   PubMed Web of Science ®Google Scholar
• Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction. J Am Coll Cardiol. 2017;70(16):1949–1961.
   PubMed Web of Science ®Google Scholar
• Kuck K-H, Merkely B, Zahn R, et al. Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure. Circ Arrhythm Electrophysiol. 2019;12(12):e007731.
   PubMed Web of Science ®Google Scholar
• Cha Y-M, Wokhlu A, Asirvatham SJ, et al. Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunctidysfunction: a comparison to systolic dysfunction and normal ventricular function. Circ Arrhythm Electrophysiol. 2011;4(5):724–732.
   PubMed Web of Science ®Google Scholar
• Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of Left Ventricular Dysfunction Following Ablation of Atrial Fibrillation. J Cardiovasc Electrophysiol. 2007;18(1):9–14.
   PubMed Web of Science ®Google Scholar
• Hsu L-F, Jaïs P, Sanders P, et al. Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure. N Engl J Med. 2004;351(23):2373–2383.
   PubMed Web of Science ®Google Scholar
• Tondo C, Mantica M, Russo G, et al. Pulmonary Vein Vestibule Ablation for the Control of Atrial Fibrillation in Patients with Impaired Left Ventricular Function. Pacing Clin Electrophysiol. 2006;29(9):962–970.
   PubMed Web of Science ®Google Scholar
• Bunch TJ, May HT, Bair TL, et al. Five-Year Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction. J Cardiovasc Electrophysiol. 2015;26(4):363–370.
   PubMed Web of Science ®Google Scholar
• Calvo N, Bisbal F, Guiu E, et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. Int J Cardiol. 2013;168(4):4093–4097.
   PubMed Web of Science ®Google Scholar
• Di Biase L, Mohanty P, Mohanty S, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device. Circulation. 2016;133(17):1637–1644.
   PubMed Web of Science ®Google Scholar
• Marrouche NF, Brachmann J, Andresen D, et al., Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417–427.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Sohns C, Zintl K, Zhao Y, et al. Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure. Circ Arrhythm Electrophysiol. 2020;13(10). 10.1161/CIRCEP.120.008461.
   PubMed Web of Science ®Google Scholar
• Packer DL, Piccini JP, Monahan KH, et al. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. Circulation. 2021;143(14):1377–1390.
   PubMed Web of Science ®Google Scholar
• Parkash R, Wells GA, Rouleau J, et al. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: results from the RAFT-AF trial. Circulation. 2022;145(23):1693–1704.
   PubMed Web of Science ®Google Scholar
• Chen S, Pürerfellner H, Meyer C, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J. 2020;41(30):2863–2873.
   PubMed Web of Science ®Google Scholar
• AlTurki A, Proietti R, Dawas A, et al. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2019;19(1). 10.1186/s12872-019-0998-2.
   PubMedGoogle Scholar
• Turagam MK, Garg J, Whang W, et al. Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure. Ann Intern Med. 2018;170(1):41–50.
   PubMed Web of Science ®Google Scholar
• Kheiri B, Osman M, Abdalla A, et al. Catheter ablation of atrial fibrillation with heart failure: an updated meta-analysis of randomized trials. Int J Cardiol. 2018;269:170–173.
   PubMed Web of Science ®Google Scholar
• Elgendy AY, Mahmoud AN, Khan MS, et al. Meta-Analysis Comparing Catheter-Guided Ablation Versus Conventional Medical Therapy for Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction. Am J Cardiol. 2018;122(5):806–813.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–e88.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305–1316.
   PubMed Web of Science ®Google Scholar
• Rillig A, Magnussen C, Ozga A-K, et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation. 2021;144(11):845–858.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498.
   PubMed Web of Science ®Google Scholar
• Gopinathannair R, Chen LY, Chung MK, et al. Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: a Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol. 2021;14(7):e000078.
   Web of Science ®Google Scholar
• Anselmino M, Matta M, D’Ascenzo F, et al. Catheter Ablation of Atrial Fibrillation in Patients With Left Ventricular Systolic Dysfunction. Circ Arrhythm Electrophysiol. 2014;7(6):1011–1018.
   PubMed Web of Science ®Google Scholar
• Briceño DF, Markman TM, Lupercio F, et al. Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol. 2018;53(1):19–29.
   PubMed Web of Science ®Google Scholar
• Huo Y, Gaspar T, Schönbauer R, et al. Low-Voltage Myocardium-Guided Ablation Trial of Persistent Atrial Fibrillation. NEJM Evidence. 2022;1(11). 10.1056/EVIDoa2200141.
   Google Scholar
• King JB, Azadani PN, Suksaranjit P, et al. Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;70(11):1311–1321.
   PubMed Web of Science ®Google Scholar
• Kim DY, Kim SH, Ryu K-H. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019;49(9):808.
   PubMed Web of Science ®Google Scholar
• Shao Q, Meng L, Lee S, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1). 10.1186/s12933-019-0964-4.
   Web of Science ®Google Scholar
• Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 2020;141(15):1227–1234.
   PubMed Web of Science ®Google Scholar
• Verma A, Boersma L, Haines DE, et al. First-in-Human Experience and Acute Procedural Outcomes Using a Novel Pulsed Field Ablation System: the PULSED AF Pilot Trial. Circ Arrhythm Electrophysiol. 2022;15(1):e010168.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Neuzil P, Koruth JS, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019;74(3):315–326.
   PubMed Web of Science ®Google Scholar
• Tison GH, Sanchez JM, Ballinger B, et al. Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch. JAMA Cardiol. 2018;3(5):409.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar